Deep learning has already had a huge impact on computer vision and speech recognition, and it’s making inroads in areas as computer-unfriendly as cooking. Now a new startup led by University of Toronto professor Brendan Frey wants to cause similar reverberations in genomic medicine.
Deep Genomics plans to identify gene variants and mutations never before observed or studied and find how these link to various diseases. And through this work the company believes it can help usher in a new era of personalized medicine.
Genomic research is hard. Scientists still know relatively little about our genes and how they interrelate. But Frey and others in the field now know enough that they can equip machines to do the heavy lifting. And there’s an awful lot of this heavy lifting to do. “Genomics is no longer about small datasets,” Frey tells Gizmag. “It’s now about very, very large datasets.”
For context, the first effort to sequence a full human genome took 13 years – running from 1990 to 2003. There are now many companies working to sequence many genomes at a time. The largest of these is called Illumina. “Illumina,” Frey says, “expects to sequence one million genomes in the next year. Each genome contains three billion letters. That’s a lot of data.”
To store and make sense of all that data, Deep Genomics built Spidex. The name is a portmanteau of “splicing index,” which basically means that Spidex is a database containing information about how lots and lots of different genetic variants affect (or are likely to affect) RNA splicing – a crucial step in gene expression that edits genes in different ways so that they can produce different kinds of proteins.
If RNA splicing goes off kilter, the consequences could range from nothing in particular to disease and cancer. Spidex is meant to help us separate the harmless variants from the harmful ones, and to understand how they relate to other genetic processes.
Spidex currently includes predictions to the tune of around 328 million such variants and the knock-on effects they pose for RNA splicing. That number is set to grow as the company applies its deep learning algorithms to classifying and interpreting more data.
Frey also notes that the bulk of those variants are in the “junk DNA” part of the genetic code. This is the bit that scientists had previously written off as irrelevant, even though it forms the vast majority of the genome. “Most medical genetic analysis currently deals only with mutations in what are called ‘protein-coding segments’ in DNA, or ‘exons,’ Frey explains. “This makes up only 1.5 percent of the genome.”
Read more: New company plans to revolutionize genomic medicine with deep learning
The Latest on: Genomic medicine
[google_news title=”” keyword=”Genomic medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Genomic medicine
- Researchers show genetic variant common among Black Americans contributes to large cardiovascular disease burdenon May 12, 2024 at 2:59 am
Researchers at Brigham and Women's Hospital and Duke University showed that a genetic variant, present in 3-4% of self-identified Black individuals in the U.S., increases the risk for both heart failu ...
- Scientists Unveil the Genetic Blueprint of Blood Pressureon May 11, 2024 at 10:13 am
Over 100 new genomic regions linked to blood pressure were discovered, offering insights into iron metabolism and potential new drug targets for treating hypertension. NIH-led study finds genetic ...
- Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Lifeon May 10, 2024 at 3:00 am
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genomics is the future of medicine. With it, companies are racing to shed ...
- Advancing The Future Of Medicine By Getting Back To Its Genetic Rootson May 9, 2024 at 12:00 pm
Regeneron is rooted in the power of genetics, technology and collaboration—the blueprint for our antibody portfolio and now, genetic medicines. Unlocking innovation to deliver life-altering therapies ...
- Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meetingon May 9, 2024 at 6:00 am
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare ...
- Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planningon May 8, 2024 at 5:00 pm
The new technology however offers the potential to significantly streamline this process, as it uses AI to automatically integrate pathological images and genomic information ... in the field of ...
- Research team identifies four new genetic risk factors for multiple system atrophyon May 8, 2024 at 2:00 pm
In a study published in Neuron, researchers have identified four new genetic risk factors for multiple system atrophy (MSA), shedding light on this poorly understood disorder. The study, which ...
- Genomics Market to be Worth $70.52 Billion by 2031--Exclusive Report by Meticulous Research®on May 8, 2024 at 7:16 am
Genomics is the study of genes and their function, including genome organization, structure, function, and evolution. It involves analyzing the DNA sequence and studying the interactions between genes ...
- Advancing genomic medicine: National Cancer Center Japan's role in personalized cancer treatmenton May 2, 2024 at 5:00 pm
In a significant stride towards personalized cancer care, the National Cancer Center Japan (NCCJ) has marked a decade of progress in cancer genomic medicine (CGM).
- GSK and Genomics collab to explore using genetics in clinical trial designon April 30, 2024 at 12:20 pm
GSK and Genomics plc will collaborate on a new precision medicine initiative that assesses how genetic data can be used in clinical trial design, Genomics ...
via Bing News